Memantine in Moderate to Severe Alzheimer’s Disease: a Meta-Analysis of Randomised Clinical Trials
Open Access
- 10 May 2007
- journal article
- research article
- Published by S. Karger AG in Dementia and Geriatric Cognitive Disorders
- Vol. 24 (1), 20-27
- https://doi.org/10.1159/000102568
Abstract
The efficacy of memantine in Alzheimer’s disease (AD) has been investigated in multiple randomised, placebo-controlled phase III trials. Recently, the indication label for memantine in Europe was extended to cover patients with moderate to severe AD, i.e. Mini-Mental State Exam total scores below 20. The efficacy data for memantine in this patient subgroup has been summarised by a meta-analysis of 1,826 patients in six trials. Efficacy was assessed using measures of global status (Clinician’s Interview-Based Impression of Change Plus Caregiver Input), cognition (Alzheimer’s Disease Assessment Scale – Cognitive Subscale, or Severe Impairment Battery), function (Alzheimer’s Disease Cooperative Study Activities of Daily Living 19- or 23-item scale), and behaviour (Neuropsychiatric Inventory). Results (without replacement of missing values) showed statistically significant effects for memantine (vs. placebo) in each domain. Memantine was well tolerated, and the overall incidence rates of adverse events were comparable to placebo. This meta-analysis supports memantine’s clinically relevant efficacy in patients with moderate to severe AD.Keywords
This publication has 20 references indexed in Scilit:
- Memantine Treatment in Mild to Moderate Alzheimer Disease: A 24-Week Randomized, Controlled TrialAmerican Journal of Geriatric Psychiatry, 2006
- Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatmentNeurology, 2006
- Mapping Scores Onto Stages: Mini-Mental State Examination and Clinical Dementia RatingAmerican Journal of Geriatric Psychiatry, 2006
- Moderate to severe Alzheimer diseaseNeurology, 2005
- Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studiesInternational Journal of Geriatric Psychiatry, 2005
- Specific Functional Effects of Memantine Treatment in Patients with Moderate to Severe Alzheimer’s DiseaseDementia and Geriatric Cognitive Disorders, 2004
- Memantine Treatment in Patients With Moderate to Severe Alzheimer Disease Already Receiving DonepezilJama-Journal Of The American Medical Association, 2004
- The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidenceInternational Journal of Geriatric Psychiatry, 2003
- Memantine in Moderate-to-Severe Alzheimer's DiseaseThe New England Journal of Medicine, 2003
- Evaluating the Driving Competence of Dementia PatientsAlzheimer Disease & Associated Disorders, 1997